News

A young father shares his experience of living with ALS

A young father shares his experience of living with ALS

If we were to ask you to pick an object defining compassion, what would you choose? For Phillipe B, it is his electric toothbrush. Recently diagnosed with amyotrophic lateral sclerosis (ALS), Phillipe shares his experience of the disease, and his vision of a life with...

Interview with Norman MacIsaac: I’m not a victim of ALS

Interview with Norman MacIsaac: I’m not a victim of ALS

I’m not a victim of ALS, I’m part of an army of people working to end ALS. We can use many words to try and define Norman MacIsaac: husband, father, friend, author, unapologetic optimist, ALS ambassador, patient advocate, leader. Today we are sharing a part of his...

Dr. Ducharme talks about the Jokers laugh

Dr. Ducharme talks about the Jokers laugh

The Joker's laughter exists for real (Translated from lapress.ca) "The laughter of the Joker, excessive and stretching inordinately over time, is not an invention of the creators of the Machiavellian character. It bears a name: the pseudobulbar affect (PBA) And some...

Parkinson Canada Superwalk

Parkinson Canada Superwalk

Parkinson Canada SuperwalkFor more than 30 years participants from across the country have come together to show one another that they are not alone. Now, guided by the relentless perseverance of people living with Parkinson's standing up to their diagnosis more than...

Burgers to Beat MS

Burgers to Beat MS

Burgers to Beat MSThe CRU and the MS clinic help raise money towards MS Research and Support programs. Thank you to Sean Carlin for organizing our participation! On August 22nd, $2 from every Teen Burger sold from A&W will go toward those living with MS.

Highest global enroller for brain tumour clinical trial

Highest global enroller for brain tumour clinical trial

Highest global enroller for brain tumour clinical trialDr. Petrecca and his team (Josephine Chu and Adrien Poulin) have received a 2018 Scimega Network Champion Award for their outstanding performance as the highest global enroller for their U.S. Biotech Sponsor’s...

CTV with Dr. Paul Giacomini on MS in Canada

CTV with Dr. Paul Giacomini on MS in Canada

Your Morning with Dr. Paul Giacomini Canada has one of the highest rates of MS in the world. Join Dr Giacomini on CTV's "Your Morning" as he talks about why MS rates are so high in Canada and what is being done to fight it.

Recent Facebook Posts

This message is only visible to admins.
Problem displaying Facebook posts. Backup cache in use.
Click to show error
Error: Error validating access token: The session has been invalidated because the user changed their password or Facebook has changed the session for security reasons. Type: OAuthException
Clinical Research Unit at the Montreal Neurological Institute-Hospital's cover photo ... See MoreSee Less
View on Facebook
The Clinical Research Unit at The Neuro is the only site in Quebec taking part in an international study which will compare a new investigational treatment to an approved medication, Ocrevus, in individuals with Primary Progressive Multiple Sclerosis (PPMS).This Phase III trial is investigating Fenebrutinib, a new therapy which uses BTK inhibitors, a promising new avenue in treatment. All participants in the trial will be on active treatment, receiving either Fenebrutinib or Ocrevus. We are looking for people aged 18 to 65 years old with PPMS. To learn more, contact (514) 398-7324 or ms-cru.neuro@mcgill.ca or visit cru.mcgill.ca/ms.__L'Unité de recherche clinique du Neuro est le seul site au Québec qui participe à une étude internationale qui comparera un nouveau traitement expérimental à un médicament approuvé, l’Ocrevus, chez les personnes atteintes de sclérose en plaques progressive primaire (SPP).Cet essai de phase III étudie le Fénébrutinib, une nouvelle thérapie qui utilise des inhibiteurs de BTK, une nouvelle voie de traitement prometteuse. Tous les participants à l'essai seront sous traitement actif, recevant soit du Fénébrutinib soit de l'Ocrevus.Nous recherchons des personnes âgées de 18 à 65 ans diagnostiquées avec la SPP. Pour en savoir plus, contactez le (514) 398-7324 ou ms-cru.neuro@mcgill.ca ou encore visitez c cru.mcgill.ca/fr/sp.#multiplesclerosis #ms #ppms #sp #sep #sppp #scleroseenplaquesThe Neuro Multiple Sclerosis Society of Canada Multiple Sclerosis West Island @SocieteSPCanada ... See MoreSee Less
View on Facebook
Research undertaken by our National Programs Manager for Genetic ALS, Kristiana Salmon, was recently published in the Journal of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. Her assessment of current genetic testing practices in ALS clinics in Canada points to a lack of harmonization in provincial regulations around the ordering of genetic tests which has led to unequal access for Canadian ALS patients. The study underscores the need to explore the feasibility of adopting a mainstream approach to genetic testing as a way to improve our understanding of the extent and true impact of genetic mutations in ALS, and also in order to identify all people living with ALS who could benefit from genetic therapies. Full article: bit.ly/alsgentestFor more on genetic ALS trials open at the CRU, visit cru.mcgill.ca/ALS.1: Brown C.A et al, 2021: doi.org/10.1159/000516752___Une étude entreprise par notre gestionnaire des programmes nationaux pour la SLA génétique, Kristiana Salmon, ont récemment été publiées dans le Journal of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. Son évaluation des pratiques courantes en matière de tests génétiques dans les cliniques de la SLA au Canada indique qu’un manque d'harmonisation des règlements provinciaux concernant la commande de tests génétiques entraîné un accès inégal pour les canadiens atteints de la SLA.L'étude souligne la nécessité d'explorer la faisabilité d'adopter une approche standardisée des tests génétiques afin d'améliorer notre compréhension de l'étendue et de l'impact réel des mutations génétiques dans la SLA, et également afin d'identifier toutes les personnes vivant avec la SLA qui pourraient bénéficier de thérapies génétiques.Article complet : bit.ly/alsgentestPour tous les essais sur la SLA génétique à l’URC, visitez cru.mcgill.ca/sla. #ALS #SLA #amyotrophiclateralsclerosis #cru #mcgill #theneuroThe Neuro McGill Faculty of Medicine and Health Sciences ... See MoreSee Less
View on Facebook
Duchenne Muscular Dystrophy (DMD) is a debilitating and ultimately fatal disease that begins in early childhood. Most individuals with DMD will be wheelchair-bound by adolescence and may not live into their 30s. There are few treatments to help with symptoms and no treatment to slow the progression of the disease. The Clinical Research Unit at The Neuro is taking part in an international Phase III trial which will evaluate the effectiveness of a new investigational drug in combination with systemic corticosteroids on symptom management in DMD. We are looking for individuals over 18 years of age with non-ambulatory DMD to take part. To learn more about the Pamrevlumab study, visit cru.mcgill.ca/neuromuscular or contact xin.dong@mcgill.ca.--La myopathie de Duchenne (DMD) est une maladie débilitante et mortelle qui apparait dans la petite enfance. La plupart des personnes atteintes de DMD seront en fauteuil roulant à l'adolescence et pourraient ne pas se rendre à la trentaine. Il existe peu de traitements pour soulager les symptômes et aucun traitement pour ralentir la progression de la maladie.L'Unité de recherche clinique du Neuro participe à un essai international de phase III qui évaluera l'efficacité d'un nouveau médicament expérimental en combinaison avec des corticostéroïdes systémiques pour la gestion des symptômes de la DMD. Nous recherchons des personnes de plus de 18 ans atteintes de DMD non ambulatoire pour participer. Pour en savoir plus sur l'étude Pamrevlumab, consultez le cru.mcgill.ca/fr/nm-2/ ou contactez xin.dong@mcgill.ca.#neuromuscular #clinicalresearch #clinicaltrials #DrugDevelopment #DMD #duchennemusculardystrophie #myopathiededuchenne #raredisease The Neuro McGill Faculty of Medicine and Health Sciences Neuromuscular Disease Network for Canada - NMD4C ... See MoreSee Less
View on Facebook
Timeline PhotosOctober 29th is World Stroke Day. Stroke is the third leading cause of death in Canada and the tenth largest contributor to disability-adjusted life years (the number of years lost due to ill-health, disability or early death).Major advances have been made in stroke treatment over the past few years. In 2015, an image-guided procedure that removes brain clots with a catheter, or endovascular thrombectomy, became standard, significantly improving therapy for acute stroke. Since then, almost 50 per cent of patients who would have been severely handicapped by the stroke now can leave the hospital with minimal disability.A trial at The Neuro’s Clinical Research Unit aims to further improve those odds. The study will examine a new treatment which aims to protect and increase viability of the brain tissue affected by the stroke. If successful, this novel treatment coupled with thrombectomy could help an even higher proportion of patients make it out with minimal disability and faster recovery.For more information on stroke trials at The Neuro, visit: cru.mcgill.ca/stroke #worldstrokeday Centre universitaire de santé McGill - McGill University Health Centre Clinical Research Unit at the Montreal Neurological Institute-Hospital Heart & Stroke ... See MoreSee Less
View on Facebook